Patients with upregulated FNDC3B presented a 64.65% recurrence rate and an average of 33.4 months recurrence time, while HCC patients without FNDC3B upregulation had a recurrence rate of 51.1% and average recurrence time of 42.53 months (p = 0.016) (Figure 3D). Here, FNDC3B is linked to hepatocellular carcinoma.